1Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonalantibody against Her- 2 for metastatic breast cancer that overexpresses Her-2[J].N Engl J Med, 2001,344(11):783-792.
2Lu C, Speers C, Zhang Y, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors [J]. J Natl Cancer lnst, 2003,95(24):1825-1833.
3Dannenberg A J, Ahorki N K, Boyle J O, et al. Cyclooxygenase-2: A pharmacologic target for the prevention of cancer [J].Lancet Oncol, 2001;2(9):544-551.
4Subbaramaiah K, Norton L, Geral W, et al.Cyclooxygenase-2 is overexpressed in Her2/neu- positive breast cancer: evidence for involvement of AP- 1 and PGA3[J]. J Biol Chem, 2002,277(21):18649-18657.
5Cross M J, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition [J]. Trends PharmacolSci, 2001,22(4):201-207.
6Subbaramaiah K, Hart J C, Norton L, et al.Microtubule- interfering agents stimulate the transcription of cyclooxygenase- 2. Evidence for involvement of ERK1/2 AND p38 mitogen- activated protein kinase pathways[J]. J Biol Chem, 2000,275(20):14838-14845.
7Fuchs I B, Lant S, Bueler H, et al. Analysis of Her- 2 and Her- 4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin)[J]. Breast Cancer Res Treat, 2003,82(1):23-28.
